EADO - European Association of Dermato-Oncology

06/10/2025

At , Prof. Dr. Swen Malte John (University of Osnabrück, Chair of the EADV Task Force on Occupational Skin Diseases) highlighted the outcomes of the 4th Multi-Stakeholder Summit on Occupational Skin Cancer, made possible by the EADO.

👥 This important summit brought together representatives from the Ministry of Health of Greece, the International Labour Organization (ILO), and the World Health Organization (WHO).

📌 The main objective: to advance recognition of skin cancer as an occupational disease, especially for outdoor workers frequently exposed to the sun. Strengthening prevention and policy efforts can significantly improve worker health worldwide.

📍The discussion continues at EADO 2026 in Prague [LINK IN BIO]

22/09/2025

🌍 We are proud to announce that the European Association of Dermato-Oncology (EADO) is now an official Member of the International League of Dermatological Societies (ILDS)!

A membership in the International League of Dermatological Societies can significantly enhance the European Association of Dermato-Oncology’s global network, foster collaboration with leading dermatology experts, and strengthen its influence in advancing the field of dermato-oncology worldwide.

This marks an exciting step forward in our mission to connect, educate, and support specialists dedicated to skin cancer and complex skin diseases—on a truly global scale.

🤝 We look forward to contributing actively to the ILDS community and shaping the future of dermatology together.

19/09/2025

🧬 Mitochondrial mutations and melanoma: a new layer of response prediction?
At , Prof. Dr. Payam Gammage, mitochondrial biologist and group leader at the CRUK Scotland Institute (Glasgow), presented emerging data on the role of mitochondrial DNA mutations in shaping tumor metabolism, immune activity, and—critically—response to immunotherapy.

📊 His lab has shown that:
– ~50% of melanomas harbor mitochondrial mutations
– These mutations significantly impact the tumor microenvironment
– Patients whose tumors carry mitochondrial DNA mutations may be 2.5× more likely to respond to checkpoint inhibitors

Despite their frequency, mitochondrial mutations remain underexplored in cancer biology—and Prof. Gammage calls for increased attention within the melanoma research community.

🧪 More data to come—see you in Prague for the 22nd EADO Congress 2026.

04/09/2025

At , Dr. Piotr Wojcieszek, radiation oncologist at the National Research Institute of Oncology in Gliwice (Poland), highlighted the role of interventional radiotherapy (brachytherapy) in the treatment of skin cancers.
📍Key points:
– Brachytherapy is used for a wide range of skin cancers, including non-melanoma, and in selected cases, melanoma, sarcoma, or cutaneous lymphomas
– Techniques include surface and interstitial approaches
– Local control can be excellent when delivered by experienced teams
🩺 His core message: radiation oncologists and brachytherapy specialists should be active contributors in multidisciplinary tumor boards, especially when exploring non-surgical strategies.
📆 See you at the 22nd EADO Congress 2026 in Prague—and don’t forget to call your brachytherapy guys.

28/08/2025

At , Dr. Javier de la Iglesia () from Hospital Clínic Barcelona () presented on pseudomyogenic hemangioendothelioma, a rare vascular tumor most commonly seen in young males, especially in the extremities, though it can also appear in other body regions.
🔬 Diagnosis relies on histopathology and immunohistochemistry, with the tumor typically showing:
✔️ Positive: AE1/AE3, ERG, CD31, FLI1
❌ Negative: S100, desmin, CD34

The tumor is low-grade malignant, often locally recurrent, but with low metastatic potential.

🛠️ Mohs surgery is the main treatment, often requiring multiple stages. In systemic cases, mTOR inhibitors such as sirolimus or tacrolimus may be considered.

📍Stay tuned for more insights and register now for the 22nd EADO Meeting 2026 in Prague [LINK IN BIO] 👈

11/08/2025

🧫 Adoptive cell therapy for metastatic melanoma: where do we go from here?
At the World Congress of Melanoma 2025, Prof. Dr. Gal Markel, Director of the Davidoff Comprehensive Cancer Center (Israel), shared key insights into the next steps for improving TIL therapy (tumor-infiltrating lymphocytes), recently approved for the treatment of metastatic melanoma.

He outlined 3 priority areas to enhance efficacy, safety, and accessibility:
1️⃣ Safety – Optimizing preparatory chemotherapy and IL-2 regimens to expand implementation across more centers and patient populations.
2️⃣ Product improvement – Leveraging epitope targeting, gene editing, and epigenetic reprogramming to develop more selective and potent TILs.
3️⃣ Manufacturing – Using advanced tech to reduce production costs and make treatment more accessible worldwide.

🧪 With multiple phase I trials and biotech investment ongoing, this is a field to watch closely.

07/08/2025

From April 23–25, 2026, we’ll meet at the O₂ Universum () in Prague, Czech Republic — one of Europe’s most modern and accessible congress centres.

Located just 10 minutes from the city centre and 30 minutes from the international airport, O₂ Universum offers cutting-edge facilities, excellent transport connections, and the capacity to host thousands of participants in a dynamic and inspiring setting.

Join us in one of Europe’s most beautiful cities for a congress experience designed for science, networking, and innovation.

🔗 Visit the Congress website at the LINK IN BIO for more details 👀

30/07/2025

🗣️ “Inoperable doesn’t mean incurable.”
At the World Congress of Melanoma 2025 in Athens, Prof. Dr. Petr Arenberger, Chair of Dermatology at Charles University in Prague, delivered a lecture on dermatosurgery—highlighting the therapeutic options available when conventional surgery or radiotherapy is no longer feasible.

🛠️ From new treatment strategies for advanced skin tumors to expanding the definition of what’s treatable, his session emphasized the broadening scope of care in complex dermato-oncological cases.

As a member of the Scientific Programming Committee, Prof. Arenberger also gave a glimpse into the planning for 22nd EADO Congress 2026 in Prague, where themes like empowering the next generation of melanoma specialists will take center stage.

📍We’re just getting started—see you in Prague next year.

12/05/2025

🎉 Announcing the New EADO President: Prof. Dr. Josep Malvehy 🎉
We are pleased to share that, as of April 2, 2025, Prof. Dr. Josep Malvehy has been appointed President of the European Association of Dermato-Oncology (EADO) . He succeeds Prof. Claus Garbe, whose leadership has been instrumental in advancing the Association’s mission.

Prof. Malvehy is the Director of the Skin Cancer Program at Hospital Clínic de Barcelona (). He has dedicated his career to advancing the diagnosis and treatment of skin tumors.

His leadership marks a new chapter for EADO, focused on collaboration, innovation, and continued excellence in dermato-oncology. We are confident his vision will further strengthen EADO’s mission across Europe and beyond.

We extend our heartfelt gratitude to Prof. Garbe for his outstanding contributions and welcome Prof. Malvehy as he leads EADO into a new era of advancement in skin cancer care.

04/05/2025

Dr. David Moreno TODAY @ ESTRO 2025 – Vienna

May 2–4. Vienna, Austria

Joint EADO–ESTRO Session at the ESTRO 2025 Congress:

“Mohs Surgery: Less is More, But Reconstruction May Still Be Needed”

Dr. David Moreno (Seville, Spain), board member of EADO, will present key insights on:

-What Mohs surgery involves

-The importance of careful patient selection to identify those who will benefit most from micrographically controlled surgery

-Why ensuring complete tumor removal is essential before undertaking complex reconstructions

-How, in selected high-risk cases, Mohs surgery may not be the final step, and adjuvant radiotherapy may improve long-term local control

-The vital role of multidisciplinary collaboration in managing challenging skin cancers

A session focused on precision, safety, and personalized care in skin cancer treatment.

07/04/2025

Onorato di partecipare a 𝟭𝟭𝘁𝗵 𝗪𝗼𝗿𝗹𝗱 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗼𝗳 𝗠𝗲𝗹𝗮𝗻𝗼𝗺𝗮, un evento fondamentale per il confronto internazionale sulla ricerca e il trattamento del melanoma.

Nel mio intervento, "𝗠𝗲𝗹𝗮𝗻𝗼𝗺𝗮 𝗴𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀 𝗮𝗿𝗼𝘂𝗻𝗱 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱", ho avuto l’opportunità di esporre le linee guida internazionali per la gestione del melanoma, sottolineando l'importanza di un approccio condiviso e sempre più efficace nella lotta contro questa patologia.

Un ringraziamento a EADO - European Association of Dermato-Oncology, Melanoma World Society "MWS" e a tutti i colleghi che contribuiscono ogni giorno a far progredire la ricerca e la cura del melanoma.

07/04/2025